Brambilla C, Colonna M Cannabis: the next villain on the lung cancer battlefield? Eur Respir J. 2008 Feb;31(2):227-8. doi: 10.1183/09031936.00157607.
Brambilla C, Sánchez-Chardi A, Pérez-Trujillo M, Julián E, Luquin M Cyclopropanation of a-mycolic acids is not required for cording in Mycobacterium brumae and Mycobacterium fallax. Microbiology. 2012 Jun;158(Pt 6):1615-1621. doi: 10.1099/mic.0.057919-0. Epub 2012 Apr 5.
Brambilla C From surgical to molecular scalpel: ERJ lung cancer series for 2009. Eur Respir J. 2009 Jan;33(1):9-10.
BRAMBILLA C , ROUSSEAUX S., DE BERNARDI A., JACQUIAU B., VITTE A.L., ARBIB F., LEMAITRE N., LANTUEJOUL S., MIGNOTTE H, MORO-SIBILOT D., TOFFART A.C., BRAMBILLA E., KOCHBIN S. A PCR-based test detecting ectopic expressions of placenta/germline genes can predict aggressive lung tumours. J. Thor. Oncol. • Volume 8, Supplement 2, November 2013 S1048
Edmond V, Brambilla C, Brambilla E, Gazzeri S, Eymin B SRSF2 is required for sodium butyrate-mediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines. Cell Cycle. 2011 Jun 15;10(12):1968-77. Epub 2011 Jun 15.
Larrieu D, Ythier D, Brambilla C, Pedeux R ING2 controls the G1 to S-phase transition by regulating p21 expression. Cell Cycle. 2010 Oct 1;9(19):3984-90. Epub 2010 Oct 1.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.